Metabolic Diseases
196 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| AI-Guided Multimodal Rehabilitation Program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Alcohol beverage for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aminohippurate Sodium Inj 20% + CANAGLIFLOZIN for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 100 mg TID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 125 mg BID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 125 mg TID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 150 mg BID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 75 mg BID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 75 mg TID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ARBs in combination of SGLT2i for diabetes mellitus | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATR-258 for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + EVOLOCUMAB for hypercholesterolemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + EVOLOCUMAB for hyperlipoproteinemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Avexitide for glucose metabolism disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Avexitide for hypoglycemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| AZD6234 for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Barley beta-glucan(3.0g) for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BBI-001 for hemochromatosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BEAM-301: Single dose of BEAM-301 administered by IV for glycogen storage disease type i | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Berberine ursodeoxycholate for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Berobenatide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Beta glucan for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Body Composition + Blood Draw + CGM/CKM + gradCPT + Ketogenic Diet + Ketone/Glucose Monitoring + NIH Toolbox + PHQ-9 + Resting-state fMRI + SKID + Sleep Monitoring + Task-fMRI + WHO-5 for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for hyperglycemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cagrilintide for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Calorie restricted diet and exercise intervention for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Calorie restriction via total food replacement for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| cfMSC therapy for diabetes for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| cfMSC therapy for diabetes for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CIL001 (Paliroden) for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clazakizumab for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clofutriben for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Continous Glucose Monitor (CGM) + Low-calorie diet + Personalized exercise program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Control for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Control for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CoolSculpting® System for lipid metabolism disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for homozygous familial hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for hyperlipoproteinemia type v | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Culturally Tailored Diabetes Prevention Program for prediabetic state | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Culturally Tailored Diabetes Prevention Program + Culturally Tailored DPP Enhanced with Socioeconomic Supports for prediabetic state | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Danuglipron for diabetes mellitus | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin + Elecoglipron for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin propanediol for iron deficiencies | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| delayed APM group recruit participants with symptoms lasting for more than 6 months for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexcom G6 Professional Continuous Glucose Monitor + INSULIN HUMAN for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexcom G6 Professional Continuous Glucose Monitor + Sliding Scale Insulin for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexcom G6 Professional Continuous Glucose Monitor + Up-Titration of Home Insulin for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Digital Intervention + Metformin for prediabetic state | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| digital prosthetic interface technology for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DMR Procedure for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DMR Procedure (Fractyl) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DR10624 Injection for hypertriglyceridemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Dulaglutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Early arthroscopic partial menisectomy group for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for iron overload | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Efzimfotase Alfa for hypophosphatasia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elecoglipron for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Eloralintide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Eloralintide for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eloralintide + Macupatide for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eloralintide + Tirzepatide for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| eloralintide and tirzepatide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Empagliflozin for ketosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Chloride for hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Decanoate for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Enlicitide Decanoate for hyperlipoproteinemia type ii | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Evolocumab for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Exercise for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exercise for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exploratory test group for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ezetimibe or ezetimibe-statin combination therapy for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ezetimibe or ezetimibe-statin combination therapy for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| fecal microbiota transplantation from healthy lean donors for metabolic syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fixed-Dose Combination Strategy for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fixed-Dose Combination Strategy for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food Security Screening & Referral Program for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food-based diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formula diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green coffee + beta-glucan for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green coffee extract for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GVHD prophylaxis regimen + RIC regimen for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Haploidentical Hematopoietic Cell Transplantation for metabolic diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HD-6277 100mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HD-6277 25mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HD-6277 50mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-dose LC-Z300-01 twice daily in blinding for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity Mediterranean diet intervention for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity Mediterranean diet intervention for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HS-20094 Injection for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hyperpolarized 13C-pyruvate for metabolic syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| icovamenib 100 mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| icovamenib 100mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inclisiran for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Insulin efsitora alfa for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 12 |
| Insulin efsitora alfa for insulin resistance | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensified medical follow-up and glucose-lowering drugs for prediabetic state | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensive lifestyle Intervention for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensive lifestyle Intervention + Meal replacement system for diabetes mellitus, type 2 | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intermittent energy restriction (IER) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intermittent fasting 5:2 + Low-carbohydrate diet + Total diet replacement for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 and K-833 for diabetes mellitus, type 2 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 and K-833 BID + K-757 and K-833 QD for diabetes mellitus, type 2 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Kenetik for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic diet intervention for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laroprovstat for dyslipidemias | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LCHF Ketogenic Diet for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| libitum diet and waiting list control group for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Liraglutide for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-calorie MIND-HK diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-dose LC-Z300-01 twice daily in blinding for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Macupatide for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MAR001 for hypertriglyceridemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Maridebart Cafraglutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Meglumine sodium succinate for diabetic ketoacidosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metreleptin for insulin resistance | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MiniMed 670G system for hypoglycemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MKP10241 for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mRNA-3927 for acidosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mRNA-3927 for propionic acidemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Napazimone for mitochondrial diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Neovasculgen® for diabetes mellitus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| obicetrapib 10 mg + ezetimibe 10 mg FDC daily for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Olezarsen for hyperlipoproteinemia type i | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oral appliance therapy for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Orforglipron for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 15 |
| Osilodrostat for adrenal hyperplasia, congenital | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oxytocin for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment. for metabolic syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Patiromer for hyperkalemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-08653944 for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PG-102 for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Established Dose from prior study, NCT03810196 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine / Topiramate Oral Product for glucose intolerance | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relacorilant for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relacorilant for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for diabetes mellitus | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Retatrutide for insulin resistance | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for metabolic diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RP-A501 for lysosomal storage diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for diabetes mellitus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Semaglutide for glucose intolerance | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for prediabetic state | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Semaglutide + Cagrilintide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Sernova Cell Pouch for hypoglycemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SHR-1918 for homozygous familial hypercholesterolemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium zirconium cyclosilicate for hyperkalemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured weight-loss program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Survodutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Test group for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tifeglipron for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time Restricted Eating (TRE) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time Restricted Eating As Treatment (TREAT) for Diabetes. for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time restricted feeding for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time-restricted eating for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for diabetes mellitus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Tirzepatide for dyslipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for metabolic syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Tirzepatide for prediabetic state | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Topical Simvastatin 2% Cream for xanthomatosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement (800kcal/day) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement (TDR) Program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tranexamic acid for iron deficiencies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treatment with Ketone Supplement for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treatment with Placebo for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treosulfan for nijmegen breakage syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for hypercholesterolemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for hyperlipoproteinemia type ii | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Very Low-calorie MIND-HK diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vicadrostat for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vitamin D supplementation for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VX-017 for hypoglycemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| WS016 for hyperkalemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zenagamtide for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zimislecel for hypoglycemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |